Assay of therapeutic doses of methotrexate in body fluids of patients with psoriasis
- PMID: 1123553
- DOI: 10.1111/1523-1747.ep12510255
Assay of therapeutic doses of methotrexate in body fluids of patients with psoriasis
Abstract
A microbiologic technique for the assay of methotrexate (MTX) in urine, serum, erythrocytes, feces, and skin is described. The accuracy of the method equals that of routine microbiologic assays of folic acid. Important differences in serum MTX levels in psoriatic patients during the 24 hours after standardized intravenous and intramuscular administration were demonstrated. Repeated intravenous doses tended to be cleared from the blood univormly. After oral doses many patients achieved peak serum levels within 2 hr. with fall of level by 4 hr. Others achieved lower levels and responded less well clinically. Persistence of high serum levels at 24 and 48 hr did not confer obvious clinical benefit or necessarily give rise to by renal function when the creatinine clearance was greater than 50 ml/min. However, impaired renal function was clearly correlated with slow clearance. Routine measurement of MTX blood levels is of value in patients with suspected malabsorption or partial renal failure.
Similar articles
-
Methotrexate in erythrocytes of patients with psoriasis.Eur J Clin Pharmacol. 1986;30(4):453-6. doi: 10.1007/BF00607959. Eur J Clin Pharmacol. 1986. PMID: 3743621
-
Pharmacokinetic profile of methotrexate in psoriatic skin via the oral or subcutaneous route using dermal microdialysis showing higher methotrexate bioavailability in psoriasis plaques than in non-lesional skin.J Eur Acad Dermatol Venereol. 2016 Sep;30(9):1537-43. doi: 10.1111/jdv.13656. Epub 2016 Mar 23. J Eur Acad Dermatol Venereol. 2016. PMID: 27005005 Clinical Trial.
-
Low-dose methotrexate kinetics in arthritis.Clin Pharmacol Ther. 1984 Mar;35(3):382-6. doi: 10.1038/clpt.1984.47. Clin Pharmacol Ther. 1984. PMID: 6697645
-
Clinical pharmacokinetics of methotrexate.Clin Pharmacokinet. 1978 Jan-Feb;3(1):1-13. doi: 10.2165/00003088-197803010-00001. Clin Pharmacokinet. 1978. PMID: 346283 Review. No abstract available.
-
[Subcutaneous methotrexate in psoriasis and psoriatic arthritis treatment].Wiad Lek. 2016;69(4):675-679. Wiad Lek. 2016. PMID: 27941209 Review. Polish.
Cited by
-
Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis.Thorax. 1991 Mar;46(3):205-7. doi: 10.1136/thx.46.3.205. Thorax. 1991. PMID: 2028435 Free PMC article. Review.
-
Serum profiles of methotrexate after its administration in children with acute lymphoblastic leukaemia.Br J Cancer. 1982 Feb;45(2):300-3. doi: 10.1038/bjc.1982.47. Br J Cancer. 1982. PMID: 6949608 Free PMC article. No abstract available.
-
The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle.Cancer Chemother Pharmacol. 1984;13(2):91-4. doi: 10.1007/BF00257121. Cancer Chemother Pharmacol. 1984. PMID: 6467500
-
A microbiological assay for the measurement of methotrexate in biological fluids.J Clin Pathol. 1983 Oct;36(10):1116-9. doi: 10.1136/jcp.36.10.1116. J Clin Pathol. 1983. PMID: 6413551 Free PMC article.
-
Clinical pharmacology of intermediate-dose oral methotrexate.Cancer Chemother Pharmacol. 1980;4(2):117-20. doi: 10.1007/BF00254032. Cancer Chemother Pharmacol. 1980. PMID: 7389057
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources